Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations.

ABSTRACT:

Background

Chagas disease (CD), caused by the parasite Trypanosoma cruzi, is a serious public health concern in Latin America. Nifurtimox and benznidazole (BZ), the only two drugs currently approved for the treatment of CD, have very low efficacies in the chronic phase of the disease and several toxic side effects. Trypanosoma cruzi strains that are naturally resistant to both drugs have been reported. We performed a comparative transcriptomic analysis of wild-type and BZ-resistant T. cruzi populations using high-throughput RNA sequencing to elucidate the metabolic pathways related to clinical drug resistance and identify promising molecular targets for the development of new drugs for treating CD.

Methods

All complementary DNA (cDNA) libraries were constructed from the epim

SUBMITTER: Lima DA 

PROVIDER: S-EPMC10204194 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature